Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

Andreas G Niethammer, Heinz Lubenau, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W Buchler, Moritz Koch, Jürgen Weitz, Walter E Haefeli and Friedrich H Schmitz-Winnenthal

Abstract

Background: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses *Salmonella typhi* Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially combines the advantages of anti-angiogenic therapy and active immunotherapy.

Methods/Design: This phase I trial examines the safety, tolerability, and immunological and clinical responses to VXM01. The randomized, placebo-controlled, double blind dose-escalation study includes up to 45 patients with locally advanced and stage IV pancreatic cancer. The patients will receive four doses of VXM01 or placebo in addition to gemcitabine as standard of care. Doses from $10^6$ cfu up to $10^{10}$ cfu of VXM01 will be evaluated in the study. An independent data safety monitoring board (DSMB) will be involved in the dose-escalation decisions. In addition to safety as primary endpoint, the VXM01-specific immune reaction, as well as clinical response parameters will be evaluated.

Discussion: The results of this study shall provide the first data regarding the safety and immunogenicity of the oral anti-VEGFR-2 vaccine VXM01 in cancer patients. They will also define the recommended dose for phase II and provide the basis for further clinical evaluation, which may also include additional cancer indications.

Trial registration: EudraCT No.: 2011-000222-29, NCT01486329, ISRCTN68809279

Keywords: DNA vaccine, Oral vaccine, Pancreatic cancer, Cancer vaccine, VEGFR-2, Anti-angiogenesis

Background

Angiogenesis contributes to solid tumor growth and metastasis [1]. Compounds like bevacizumab and others, for example small molecules such as sunitinib and axitinib that specifically target the tumor neovasculature have shown efficacy in a range of tumor indications [2-4]. Tumor neovasculature is lined with endothelial cells that are overexpressing vascular endothelial growth factor receptor (VEGFR) 2 and are readily accessible via the blood stream [5]. The genetic stability of those cells and their ability to support hundreds of tumor cells per endothelial cell make them a prime target for anti-cancer therapy, be it via antibodies, tyrosine kinase inhibitors, or vaccines [6].

Recently, T-cell based immunotherapy has gained some clinical success in prostate cancer and validated the potential of anti-cancer vaccination which was often
demonstrated preclinically [7]. Activating the immune system against cancer cells faces multiple challenges. For example, cancerous lesions are often polyclonal and cancer cells have the propensity to mutate. Antigen specific therapy often only results in a selection of non-antigen bearing cells. Further hurdles include tumor encapsulation and loss or down-regulation of MHC molecules. Vaccination approaches that target that the tumor neo-vascularature should in theory overcome these hurdles.

The trial presented here attempts to combine anti-angiogenic therapy and vaccination, targeting VEGFR-2 using a new vaccine (VXM01). Hypothetically, vaccination with VXM01 should lead to breakdown of existing tumor vasculature and support the development of an immune memory against proliferating endothelial cells.

In 2002, we published a preclinical study combining anti-angiogenic therapy and vaccination for the first time [8]. Vaccinating mice against the VEGFR-2 induced strong resistance against a variety of different tumor challenges such as melanoma, colon cancer, and lung cancer, both in prophylactic as well as therapeutic experimental settings. These effects were long-lived and mediated by cytotoxic T-cells. Surprisingly, a slight delay in wound healing was the only toxicity that was observed.

To our knowledge, this is the first clinical trial of an oral cancer vaccine. In addition, this vaccine has the potential to be effective against multiple tumor types.

Methods

Preclinical efficacy assessment

The efficacy and safety of this approach in animals has been validated multiple times by us and others [8-10]. Further, own unpublished experiments showed an activity of this vaccine in two different models of pancreatic cancer.

VXM01, the vaccine used in this trial, is a humanized version of the anti-VEGFR-2 vaccine previously tested in mice. It encodes the human full-length VEGFR-2 and uses the licensed Salmonella typhi strain Ty21a instead of Salmonella typhimurium as a carrier. The vaccine is assumed to lead to VEGFR-2 protein expression in monocytes and dendritic cells after entry of VXM01 in the Peyer’s patches via M cells of the gut, and internalization by antigen-presenting cells followed by translation of the encoded DNA [11,12].

Preclinical safety assessment

Preclinical toxicity studies in mice included, but were not restricted to a single dose toxicity study in mice conducted with the human vaccine VXM01. As VXM01 is specific for the human host, the study of the human vaccine in mice focused on possible effects of process-related impurities and related signs and symptoms of possible relevance for cardiovascular, respiratory, or central nervous system impairment. In order to investigate the toxicity profile of an anti-VEGFR-2 T-cell response, a repeated dose toxicity study was conducted using the murine analog construct of VXM01 which induced a dose-dependent T-cell response in mice. In accordance to our previous observations, no treatment-related deaths and no toxicologically important clinical signs were observed throughout these studies, which were conducted according to Good Laboratory Practice (GLP).

The vector Salmonella typhi Ty21a used here is a live, attenuated bacterial carrier that allows for the oral delivery of the vaccine VXM01. It is itself an approved vaccine against typhoid fever (Vivotif®, Crucell, formerly Berna Biotech Ltd., Switzerland) that has been extensively tested and has demonstrated its safety regarding patient toxicity as well as transmission to third parties [13,14]. VXM01 is classified as a gene transfer medicinal product and subject to the respective guidance and regulations [15].

This study has been approved by the German regulatory agency, the Paul-Ehrlich-Institute (PEI). In accordance with the Declaration of Helsinki [16], the German Drug Law (Arzneimittelgesetz [AMG]) [15], the German Good Clinical Practice guideline (GCP-V) [17], and the Note for Guidance on Good Clinical Practice (GCP) [18], the study was presented to the responsible Ethics Committee of the Medical Faculty of the University of Heidelberg and the PEI. The opinion of the ethics committee and the authorization of the PEI were obtained prior to any study-related procedures. The recruiting study center is the Clinic of General Surgery; drug exposure is done and patients are supervised at the ISO-certified Clinical Research Unit (KliPS) of the Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany. Study patients will be hospitalized for ten days in KliPS during the sensitive administration period of the vaccine.

Study description

This is a monocenter, placebo controlled, double blind dose escalation study of the experimental vaccine VXM01 in patients with advanced inoperable or stage IV pancreatic cancer. The vaccine will be given as add-on to a standard of care gemcitabine treatment.

Study objectives

The objectives are to examine the safety and tolerability, and immunological and clinical responses to the investigational anti-VEGFR-2 vaccine VXM01, as well as to identify the maximum tolerated dose (MTD) of VXM01. The MTD is defined as the highest dose level at which
less than two of up to six patients under VXM01 treatment experience a dose-limiting toxicity (DLT).

Primary endpoints for safety and tolerability are as follows: Number of DLTs defined as any adverse event (AE) related to study drug of grade 4 or higher, or grade 3 or higher for gastrointestinal fistula, diarrhea, gastrointestinal perforation, multi-organ failure, anaphylaxis, any auto-immune disorder, cytokine-release syndrome, intestinal bleeding, renal failure, proteinuria, thromboembolic events, stroke, heart failure, or vasculitis according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) [19].

Secondary endpoints, which assess the efficacy of the experimental vaccine to elicit a specific immune response to VEGFR-2, include the number of immune positive patients.

A further secondary endpoint will be the clinical response: Tumor staging according to the response evaluation criteria in solid tumors (RECIST) [20], overall response rate, progression free survival, overall survival, and changes in tumor perfusion. Tumor perfusion will be determined by dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) [21] on a 1.5 Tesla system (Magnetom Aera, Siemens, Erlangen, Germany).

Investigational products
VXM01 has been manufactured according to Good Manufacturing Practice (GMP) and is given in a buffered solution. The placebo control consists of isotonic sodium chloride solution.

Patient selection and study design
This study will include a maximum of 45 patients with either locally advanced and inoperable or stage IV pancreatic cancer. The eligibility criteria are summarized in Table 1.

Male and postmenopausal female patients will be enrolled in this study. However, differences between the two genders will not be investigated. The average survival time of the patients participating in this trial is under 6 months. However, the follow-up period for the patients as defined per protocol is up to 24 months. The study treatment might confer clinical benefit and is given first-line as an add-on to standard of care. Taking further into account other factors, among them the multiple primary and secondary pharmacodynamic preclinical studies, the risk-benefit analysis is assumed to have a favorable result for the patient population selected.

The patient population and the study design were discussed in National Scientific Advice meetings with the Uppsala, Sweden) and were considered adequate to achieve the study objectives. The first administration of a gene transfer medicinal product cannot be justified in healthy volunteers.

The starting dose consists of a solution containing $10^6$ colony forming units (CFU) of VXM01 or placebo. This VXM01 dose was chosen for safety reasons and is assumed to be below the minimal effective dose to elicit an immune response. For comparison, one dose of Typhoral®, the licensed vaccine against typhoid fever, contains $2\times 10^9$ to $6\times 10^6$CFU of Salmonella typhi Ty21a, equivalent to approximately thousand times the VXM01 starting dose [22]. The dose will be escalated in factor-of-ten logarithmic steps, which appears to be justified for a live bacterial vaccine.

Complying with guidelines of first in human trials [23], the patients of one dose group will be treated in cohorts. The first administration of VXM01 in any dose group will be given to one patient only accompanied by one patient receiving placebo. The second cohort of each dose group consists of two patients receiving VXM01 and one patient receiving placebo. This staggered administration with one front-runner, i.e. only one patient receiving VXM01 first, serves to mitigate the risks [23]. A third cohort of patients (three receiving VXM01 and one receiving placebo) will be included in the $10^5$, $10^6$, and $10^{10}$ dose groups. This approach minimizes exposure to VXM01 doses assumed to be sub-therapeutic. The third cohort and the first two cohorts of the next higher treatment group may be treated in parallel based on a clearly defined randomization strategy. This strategy allows for recruitment of available patients and avoids selection bias for patients treated in parallel in the lower and higher dose group. In the $10^5$ and $10^7$ dose groups, a third cohort of patients will be included only if one patient out of the initial three patients receiving VXM01 of the respective dose group experiences a DLT and requires confirmation by a decision of the Data Safety Monitoring Board (DSMB). The study design is depicted in Figure 1.

The environmental risk inherent to an oral vaccine is the potential of excretion to the environment and subsequent vaccination of people outside the target population. All study patients will be confined in the study site (KliIPS) for the period during which vaccinations take place plus three additional days. All feces of study patients will be collected and incinerated. Body fluids and feces samples will be investigated for VXM01 shedding. As documented in the literature Ty21a, the bacterial carrier of VXM01 was not excreted up to a dose of $10^6$ cfu After administration of a dose of $10^{10}$ cfu of Ty21a fecal excretion was observed until two days after vaccination [24].

Hygienic precautions will be applied to protect study personnel from accidental uptake. Study personnel will be trained specifically for this aspect of the study.
Patients will only be discharged from hospital if they test negative for excretion of the vaccine after the last administration of the study drug. In case a patient tests positive for excretion after the last administration, an antibiotic decontamination of the gastrointestinal tract will be conducted before the patient is discharged. Excretion will be followed up until results are negative. These measures appear to be justified and sufficient to protect the environment and study personnel from exposure to VXM01 until the shedding profile has been elucidated.

VXM01 will be applied in parallel to the gemcitabine background therapy as shown in Figure 2 (overall study scheme). In brief, gemcitabine is given on days 1, 8, and

Table 1 Eligibility Criteria

| Inclusion Criteria |
|--------------------|
| 1 Written informed consent, signed and dated |
| 2 Locally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations |
| 3 Male or post-menopausal female |
| 4 Age ≥ 18 years |
| 5 Chemotherapy naïve within 60 days before screening visit except gemcitabine treatment |
| 6 Karnofsky index > 70 |
| 7 Life expectancy > 3 months |
| 8 Adequate renal, hepatic, and bone marrow function |
| 9 Absolute neutrophil count > 1500/μL |
| 10 Hemoglobin > 10 g/dL |
| 11 Platelets > 75000/μL |
| 12 Prothrombin time and international normalized ratio (INR) < 1.5 times upper limit of normal (ULN) (except under anticoagulant treatment) |
| 13 Aspartate aminotransferase < 4 times ULN |
| 14 Alanine aminotransferase < 4 times ULN |
| 15 Total bilirubin < 3 times ULN |
| 16 Creatinine clearance estimated according to Cockcroft-Gault > 30 mL/min |
| 17 Proteinuria < 1 g protein on 24 h urine collection |

| Exclusion Criteria |
|--------------------|
| 1 State after pancreas resection (complete or partial) |
| 2 Resectable disease |
| 3 Drug trial participation within 60 days before screening visit |
| 4 Other previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years |
| 5 Prior vaccination with Ty21a |
| 6 Cardiovascular disease defined as: |
|   - Uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) |
|   - Arterial thromboembolic event within 6 months before randomization including: |
|     - Myocardial infarction |
|     - Unstable angina pectoris |
|     - Cerebrovascular accident |
|     - Transient ischemic attack |
| 7 Congestive heart failure New York Heart Association grade III to IV |
| 8 Serious ventricular arrhythmia requiring medication |
| 9 Clinically significant peripheral artery disease > grade 2b according to Fontaine |
| 10 Hemoptysis within 6 months before randomization |
| 11 Esophageal varices |
| 12 Upper or lower gastrointestinal bleeding within 6 months before randomization |

Table 1 Eligibility Criteria (Continued)

| Exclusion Criteria (Continued) |
|--------------------------------|
| 13 Significant traumatic injury within 4 weeks before randomization |
| 14 Non-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion |
| 15 Gastrointestinal fistula |
| 16 Thrombolysis therapy within 4 weeks before randomization |
| 17 Bowel obstruction within the last 30 days before screening visit |
| 18 Liver cirrhosis ≥ grade B according to Child-Pugh Score-Classification |
| 19 Presence of any acute or chronic systemic infection |
| 20 Radiotherapy within 4 weeks before randomization |
| 21 Major surgical procedures, or open biopsy within 4 weeks before randomization |
| 22 Fine needle aspiration within 7 days before randomization |
| 23 Chronic concurrent therapy within 2 weeks before and during the double-blind study period with: |
|   - Corticosteroids (except steroids for adrenal failure) or immunosuppressive agents |
|   - Antibiotics |
|   - Bevacizumab |
|   - Any epidermal growth factor receptor inhibitor |
|   - Chemotherapy except gemcitabine before Day 10 |
| 24 Multi-drug resistant gram-negative germ |
| 25 Pregnancy |
| 26 Lactation |
| 27 Inability to comply with study and/or follow-up procedures |
| 28 History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications |
| 29 Women of childbearing potential |
| 30 Any history of drug hypersensitivity |
| 31 Any condition which results in an undue risk for the patient during the study participation according to the investigator |

Patients will only be discharged from hospital if they test negative for excretion of the vaccine after the last administration of the study drug. In case a patient tests positive for excretion after the last administration, an antibiotic decontamination of the gastrointestinal tract will be conducted before the patient is discharged. Excretion will be followed up until results are negative. These measures appear to be justified and sufficient to protect the environment and study personnel from exposure to VXM01 until the shedding profile has been elucidated. VXM01 will be applied in parallel to the gemcitabine background therapy as shown in Figure 2 (overall study scheme). In brief, gemcitabine is given on days 1, 8, and...
15 of a 28 days chemotherapy cycle. The vaccine will be given four times on days 1, 3, 5, and 7, starting three days after the last dose of gemcitabine. The double blinded phase of the study will end 31 days after the last patient has received the last administration.

Discussion
This study aims to find a safe and effective dose of the experimental oral vaccine VXM01 targeting the human VEGFR-2 for use during further investigation in a phase II clinical trial. Despite years of failure, a first active immune therapy, Dendreon’s Provenge, was efficacious in prostate cancer, and as a consequence has been approved by the FDA [25]. Several more tumor vaccines are now in the midst or entering late-stage development [26]. However, all these approaches are targeting so-called tumor-associated antigens (TAA). For example, vaccines targeting MUC-1 (stimuvax) and the TAA Mage-A3 are currently under development in phase III clinical trials [27,28].

VXM01 represents a novel strategy by targeting not a tumor cell-resident antigen, but a tumor stroma-resident antigen, overexpressed by non-malignant endothelial cells of the tumor neovascularure. A Japanese group has recently published a phase I study, implementing a single VEGFR-2-derived peptide administered in weekly intervals via the subcutaneous route of administration, thus following a similar approach, but restricting it to a certain HLA type [29].

By targeting genetically stable and easily accessible endothelial cells, this product aims to overcome limitations encountered previously by vaccines targeting tumor cells directly, such as to tumor-cell heterogeneity, MHC-loss, immunosupression on a cellular level and tumor encapsulation as well as physiological barriers such as the blood brain barrier. Furthermore, since the therapeutic target is independent of the tumor type, the vaccine may potentially be active against a variety of different solid malignancies. The product represents a patient-independent, “off-the-shelf” oral vaccine, which can be stored and distributed to the clinical sites for use. While anti-angiogenic therapy, either via small molecules or via antibodies, has already been proven to be effective, our approach differs significantly by activating the patient’s own immune system against tumor neovascularure and is as such potentially creating a T-cell memory effect that provides long-term efficacy. Studies with bevacizumab in colon and ovarian cancer suggest that continued anti-angiogenic pressure is required to maintain beneficial treatment effects in the long term [30-32].

Should adverse events occur that resemble hypersensitivity reactions mediated by histamine, leukotrienes, or
cytokines, treatment options for fever, anaphylaxis, blood pressure instability, bronchospasm, and dyspnoea are available. Treatment options in case of unwanted T-cell derived autoaggression are derived from standard treatment schemes in acute and chronic graft vs. host disease applied after stem cell transplantation. Cyclosporin and glucocorticoids are proposed as treatment options.

In the unlikely case of systemic *Salmonella typhi* Ty21a type infection, appropriate antibiotic therapy with fluoroquinolones including ciprofloxacin or ofloxacin is recommended [33]. Bacterial infections of the gastrointestinal tract are to be treated with rifaximin.

For this phase I trial (advanced or stage IV pancreatic cancer patients) a patient population with dismal prognosis and the relatively gentle standard of care with regard to immunosuppression was chosen. Co-regimes of gemcitabine with tumor vaccination have even been reported to be synergistic [34,35]. In addition, specific T-cell activation can be measured in this patient setting and may give an early indication of potential effectiveness of the vaccine VXM01. By including a placebo control in the present trial, we will gain further knowledge on specific safety issues related to the active vaccine vs. the background treatment. In addition, the pooled placebo patients will serve as a sound comparator in order to assess specific immune activation and other signs of clinical efficacy. If and when moving into phase II, a different patient entity with a longer life expectancy can be envisaged depending on the observed safety profile. Such studies will also include tumor types that have shown to be more susceptible to anti-angiogenic treatment.

We recognize the limitations inherent with a single center study and hope to partially address any bias by the introduction of the blinded placebo patients and an independent unblinded DSMB, which is without direct patient access. Further, the lack of a clear expectation as to what constitutes a sufficient positive immune reaction may be viewed as problematic. However, the read-out allows for a proof of a successful specific immune reaction. We have set predefined thresholds as to the positivity of our immunological assays. As to how far this can be correlated with dose and/or patient’s response remains to be seen.

**Conclusions**

VXM01 has the potential to target a variety of tumor types and to overcome multiple hurdles encountered by other present cancer vaccine approaches. A tempting vision is the possibility of combining our vaccine with a multitude of other anti-cancer and immune-modulatory
agents, provided that the toxicity profile encountered in humans will allow so.

The results of the here presented study will guide us to either modify our approach or to move forward into the next steps of clinical development.

Competing interests
This study is sponsored by VAXIMM. AG Niethammer holds stock options of VAXIMM. H. Lubenau is an employee of VAXIMM and holds stock options. M. Springer is an employee of VAXIMM and holds stock options.

Authors’ contributions
AGN was involved in preclinical studies, the design of the trial, and in the drafting of the protocol and the manuscript. HL was involved in the design, submission, implementation, coordination of the trial, and in the drafting of the protocol and the manuscript. MS was coordinating the preclinical toxicity studies, the setup of the immune monitoring and biodistribution part of the trial and contributed to the drafting of the manuscript. LG has developed the MR protocol for DCE-MRI and is responsible for imaging evaluation of the functional MR dataset and post processing of the trial and contributed to the drafting of the manuscript. MK is involved in the supervision of the trial and revised the manuscript. PK was involved in the implementation and coordination of the trial. MWB is involved in the supervision of the trial and revised the manuscript. WEH was involved in the design, implementation, submission of the trial, and in the drafting of the protocol and the manuscript. GM contributed to the design and coordination of the trial, and to the drafting of the protocol and the manuscript. NH was involved in the preparation and conduct of the trial. FHSW was involved in preclinical studies, the design, implementation, submission of the trial, in the drafting of the protocol, the manuscript and is the PI of the running trial. All authors read and approved the final manuscript.

Acknowledgements
Thanks to the members of the Data Safety Monitoring Board Prof A. Engert (Chairman), Cologne, Germany, Prof Christoph Huber, Mainz, Germany, and Prof M. Kieser, Heidelberg, Germany. Trial monitoring and pharmacovigilance is done by the KKS Heidelberg. Patient screening and recruitment is done by the KSC Heidelberg.

Author details
1VAXIMM, Mannheim, Germany. 2Clinical Pharmacology and Pharmacoepidemiology University of Heidelberg, Heidelberg, Germany. 3General, Visceral and Transplantation Surgery University of Heidelberg, Heidelberg, Germany. 4National Center for Tumor Disease University of Heidelberg, Heidelberg, Germany. 5Department of Diagnostic and Interventional Radiology University of Heidelberg, Heidelberg, Germany.

Received: 11 February 2012 Accepted: 17 July 2012

References
1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1997, 285(21):1182–1186.
2. Summary of Product Characteristics of Avastin®. 2011. http://www.medicines.org.uk/emc/medicine/15748/SPC/.
3. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T: Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011, 104(5):741–745.
4. Rini BI, Escudier B, Tomczak P, Caprini A, Szczylik C, Hutson TE, Michaelson MD, Gorbounova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lin HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931–1939.
5. Kampen KR: The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anticancer Drugs 2012, (Epub ahead of print).
6. Augustin H: Antiangiogenic tumor therapy: will it work? Trends Pharmacol Sci 1998, 19:216–222.
7. Sharma P, Wagner K, Wolchok JD, Allison JP: Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11:805–812.
8. Niethammer AG, Xiang R, Becker JC, Wodrich H, Perni U, Karsten G, Elienci BP, Reifeld RA: A DNA vaccine against vascular endothelial growth factor receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Medicine 2002, 8(12):1369–1375.
9. Li Y, Wang MN, King K, Basi R, Sun H, Santiago A, Hooper A, Bohlen P, Hicklin D: Active immunization against the vascular endothelial growth factor receptor fkl1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002, 195:1575–1584.
10. Zu QG, Chen Y, Wu ZP, Liu X, Liu C, Zhou YC, Wu CL, Jin CG, Gu YL, Li J, Chen XQ, Li Y, Wei HP, Li LH, Wang XC: Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol Pharm Bull 2010, 33(1):174–182.
11. Reifeld RA, Niethammer AG, Yunping L, Rong X: DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol Rev 2004, 199:181–190.
12. Yridl U, Wick MJ: Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J Exp Med 2000, 191:613–623.
13. Wahdan M, Sener C, Censor Y: A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three-year results. J Infect Dis 1982, 145:292–295.
14. Gardlik R, Behulak M, Paffly R, Celer P, Li CJ: Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther 2011, 18:425–431.
15. ANG, German Drug Law: "Gesetz über den Verkehr mit Arzneimitteln." Neugefasst 12. Bundesgesetzblatt, 2005:3394. last changed May 25, 2011 (BGBl I p 546). http://www.gesetze-im-internet.de/bundesrecht/ang_1976/gesamt.pdf.
16. World Medical Association: Declaration of Helsinki: Ethical principles for medical research involving human subjects. Somerset West: Republic of South Africa; 1996.
17. Verordnung über die Anwendung der Guten klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Arzneimitteln zur Anwendung am Menschen (GCP-Verordnung). 2004. BGBl. I S. 581, last changed on November 03, 2006 (BGBl. I S. 2523). http://www.gesetze-im-internet.de/bundesrecht/gcp-v/gesamt.pdf.
18. Note for Guidance on Good Clinical Practice (ICH E6 (R1)) CPMP/ICH/135/95, 1997. 2002. http://www.emea.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500020747.pdf.
19. Common Terminology Criteria for Adverse Events. (CTCAE) Version 4.0. 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Browne KK, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228–247.
21. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Byant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorone EG, Fox F, Yousoufian H, Rovinsky EK, Eckhardt SG: Phase I pharmacologic and biologic study of ramucirumab (IMC-1128B), a fully human immunoglobulinG1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28:790–787.
22. Summary of Product Characteristics of Typhoral®. 2008. http://www.fachinfo.de/view/FTNR0=0021868&L=Typhoral%26reg%3B%20L.
23. Guidelines on Strategy to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products. EMEA/CHMP/519/WP/2867/07, 2007. http://www.emea.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500002988.pdf.
24. Gilman R, Hornick R, Woodward W, DuPont H, Snyder M, Levine M, Libonati C, Youssoufian H, Rowinsky EK, Eckhardt SG: Oral administration of an intravenous monoclonal antibody specific for vascular endothelial growth factor receptor-2 as a live oral vaccine. J Infect Dis 1997, 176:717–723.
25. Cheever MA, Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011, 17:3520–3526.
26. Matejuk A, Leng Q, Chou S, Mixson A: Vaccines targeting the neovasculature of tumors. *Vascular Cell* 2011, 3:7.

27. Decoster L, Wauters I, Vansteenkiste JF: Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. *Ann Oncol* 2011, [Epub ahead of print].

28. Bichard VG, Lejeune D: GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. *Vaccine* 2007, 25(Suppl 2):B61–B71.

29. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Nakamura Y, Yamaue H: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. *Cancer Science* 2009, doi:10.1111/j.1349-7006.2009.01416.x.

30. Allegre CJ, Yohers G, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O’Reilly S, Chu L, Azar CA, Lopa S, Wolmark N: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. *J Clin Oncol* 2011, 29:1–16.

31. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011, 365:2473–2483.

32. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, du Bois A, Sestig J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Lemenen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, ICON7 Investigators: A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med* 2011, 365:2484–2496.

33. Bhan M, Bahl R, Bhatnagar S: Typhoid and paratyphoid fever. *Lancet* 2005, 366:749–762.

34. Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, Ohno E, Ishikawa T, Matsubara H, Ishitomi M, Kano Y, Ohmiya N, Niwa Y, Norimoto K, Kaneko T, Nieda M, Yokokawa K, Goto H: A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. *Pancreas* 2009, 38:69–74.

35. Soeda A, Morita-Hoshii Y, Makiyama H, Morigane C, Ueno H, Ikeda M, Okusaka T, Yamaqata S, Takahashi N, Hyodo I, Takeya Y, Heike Y: Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. *Jpn J Clin Oncol* 2009, 39:797–806.

Cite this article as: Niethammer et al.: Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. *BMC Cancer* 2012 12:361.